New Delhi: Biotech firm Biocon on Monday said its unit 'Clinigene International' has inked a pact with US-based Spaulding Clinical Research to jointly offer clinical research solutions to both pharma as well as biotech firms.

This partnership establishes a cost-efficient global footprint for clinical pharmacology services, providing an opportunity for both organisations to engage pharmaceutical clients strategically, Biocon said in a statement.

Clinigene Chief Operating Officer Abhijit Barve said, "Pharmaceutical clients globally are increasingly seeking strategies to expedite their early clinical development, streamlining processes while maintaining high quality.

"Our strategic partnership is designed to deliver this in a very cost-effective manner."

The company, however, did not disclose financial details.

"With Clinigene's expertise and cost-effective approach ...our clients are able to easily structure a program for their compound that delivers high-value value," Spaulding Clinical CEO Randol Spaulding said.

Shares of Biocon on Monday closed at Rs 329.20 on the Bombay Stock Exchange, up 2.01 per cent from its previous close.